Ind-Swift Laboratories Limited
Registered Office
SCO 850, Shivalik Enclave,
NAC Manimajra, Sector 13,
Chandigarh – 160101 INDIA
info@indswiftlabs.com
0172-2730503, 2730920, 5061851-53
CIN No. L24232CH1995PLC015553

One World One Health One Ind-Swift

Date: July 29, 2026

To,
Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai – 400001, India

Scrip Code: 532305

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C/2,
G-Block, Bandra Kurla Complex, Bandra (E),
Mumbai – 400051, India

Symbol: INDSWFTLAB

Subject: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Corrigendum to the Notice of 01/2026-27 Extra-Ordinary General Meeting (“EGM Notice”) dated July 10, 2026.

Dear Sir/Ma’am,

In continuation to our intimation dated July 14, 2026, we are hereby submitting the Corrigendum to the Notice of the Extra Ordinary General Meeting (“EGM”) scheduled to be held on Wednesday, August 05, 2026, at 11:30 A.M. (IST) through Video Conferencing (“VC”)/Other Audio-Visual Means (“OAVM”).

A Corrigendum has been issued to inform the Shareholders of the Company regarding the changes in Item No. 1 of the EGM Notice. The same is enclosed herewith.

All other particulars and details mentioned in the EGM Notice shall remain unchanged. The Corrigendum shall be read in conjunction with the EGM Notice dated July 10, 2026, together with the Explanatory Statement. This Corrigendum is also available on the Company’s website viz. www.indswiftgroup.com , and on the website of BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively. All Capitalized words and expressions used but not defined herein shall have the same meaning as assigned to them in the EGM Notice.

You are requested to take the same on your record.

Thanking You,
For Ind-Swift Laboratories Limited

PARDEEP VERMA
Digitally signed by PARDEEP VERMA
Date: 2026.07.29 18:34:57 +05'30'

Ind-Swift Laboratories Ltd. CHANDIGARH

Pardeep Verma
VP - Corporate Affairs & Company Secretary

IND-SWIFT LABOPRATORIES LIMITED
CIN: L24232CH1995PLC015553
Registered Office: SCO:850, Shivalik Enclave, NAC, Manimajra, Chandigarh – 160101, India
Email: investor@indswiftlabs.com **Website:** www.indswiftgroup.com

Corrigendum to the Notice of the Extra Ordinary General Meeting ("EGM Notice") dated July 10, 2026, for the members of Ind-Swift Laboratories Limited ("the Company") to be held on Wednesday, August 05, 2026, at 11:30 A.M. IST through Video Conferencing ("VC")/ Other Audio - Visual Means ("OAVM").

Dear Members,

This is in continuation to the Notice of Extra Ordinary General Meeting **("EGM Notice")** dated July 10, 2026, convening Extra Ordinary General Meeting of the members of Ind-Swift Laboratories Limited **("the Company")** to be held on Wednesday, August 05, 2026, for seeking approval for matters contained in the said Notice. The Notice of the EGM was dispatched to the shareholders of the Company in due compliance with the provisions of the Companies Act, 2013, and rules made thereunder, read with circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India.

In this regard we would like to mention that with regard to Item No. 01 of the same, the Company had filed application with the BSE Limited **("BSE")** and National Stock Exchange of India Limited **("NSE")** (hereinafter collectively referred to as **"Stock Exchanges"**), for seeking In-principle approval in relation to the proposed Preferential Issue of 70,00,000 Fully Convertible Warrants to entity belonging to 'Promoter & Promoter Group', for which the approval of the shareholders is being sought. Thereafter, the Company received certain observations from BSE and NSE. This Corrigendum is being issued pursuant to the observations of both the stock exchanges.

The Company through this communication wishes to bring to the notice of the Shareholders, the following changes in Item No. 01 of the said EGM Notice and Explanatory Statement:

<u>Changes to the Explanatory Statement</u>

A. Point No. I titled *'Objects of the Preferential Issue'* of the Explanatory Statement to the EGM Notice shall be substituted and read as under:

The Company is a research-led pharmaceutical company wherein we manufacture a wide range of formulations, including tablets, capsules, ointments, liquids and dry syrups at our facilities located at Jawaharpur, Derabassi (PB); Parwanoo (H.P.) and Jammu (J&K), including a 100% Export-Oriented Global Business Unit (GBU) at Derabassi (PB). In order to expand its current facilities and support future product development initiatives, the Company intends to utilize the proceeds raised through the issue of Fully Convertible Warrants **("Issue Proceeds")** towards following objects:

1. **Expansion of Business:**

   a. **Expansion of Existing Manufacturing Facility and Setting up of Warehouse**: As mentioned above, company has its existing manufacturing facility located at Jawaharpur, Derabassi (PB) and Jammu (J&K) wherein it is proposing to expand manufacturing capacity of these facilities along with setting up of a new Warehouse at Jawaharpur, Derabassi (PB), adjoining our existing manufacturing facility.

b. **Research & Development ('R&D'):** Being a pharmaceutical Company, it has to continuously engage in R&D activities, thus, a portion of the Issue proceeds is proposed to be utilised in the R&D of new pharmaceutical formulations and purchase of pilot scale formulation equipment and analytical equipment for R&D of these formulations.

c. **Technology Upgradation:** The Company is proposing to utilise part of proceeds towards (i) Implementation and customization of SAP systems and (ii) Development and deployment of Building Management Systems at the Plants of the Company.

d. **Investment in our subsidiary:** The Company is proposing to make investment in one of its subsidiaries namely ISLL Middle East LLC-FZ, Dubai. Our subsidiary would utilise the said infused amount for its Marketing and Business Development.

2. To meet the **Working Capital Requirements** of the Company.

3. **General Corporate Purposes** subject to such utilisation not exceeding 25% of the total consideration.

*(Hereinafter collectively referred to as "**Objects**")*

Utilization of Proceeds

Given that the funds to be received against Warrants, the Issue Proceeds shall be received by the Company in tranches depending upon the subscription and conversion of Warrants. Since the funds to be received against Warrant conversion will be in stages and the quantum of funds required at different points of time may vary, the broad range of intended utilization of the Issue Proceeds towards the aforesaid Objects of the Issue has been set out here in below:

S. No.	Particulars	Estimated utilization of the Issue Proceeds (Rs. in Crore) *	Tentative timeline for utilization of issue proceeds from the date of receipt of funds
1.	Expansion of Business		
	a. Expansion of Existing Manufacturing Facility and Setting up of a new Warehouse	41.40	December 31, 2029
	b. Research & Development ('R&D')	2.00	
	c. Technology Upgradation	1.50	
	d. Investment in subsidiary	5.00	
2.	To meet the Working Capital Requirements of the Company.	53.00	December 31, 2028
3.	General Corporate Purposes	34.30	December 31, 2028
Total		**137.20**	

(*) considering 100% conversion of Warrants into Equity Shares within the stipulated time.

Given that the Preferential Issue is for Warrants, the entire Issue Proceeds from the Proposed Allottee will be received by the Company within 18 months from the date of allotment of Warrants in terms of Chapter V of SEBI (ICDR) Regulations, and as estimated by the Company's management, the entire Issue Proceeds would be utilized for all the aforementioned objects, in phases, as per the Company's business requirements and availability of Issue Proceeds.

Schedule of Implementation and Deployment of Funds

Our Company, in accordance with the policies formulated and in accordance with the applicable laws and guidelines and description as given in this Notice, will have the flexibility to deploy the proceeds. Pending utilization of the proceeds for the purposes described above, our Company intends to deposit the Gross Proceeds only with scheduled commercial banks included in the second schedule of the Reserve Bank of India Act, 1934.

B. Additions in Point No. XIII titled *'Undertakings'* of the Explanatory Statement to the EGM Notice

The following two points shall be added in the Undertakings head along with the already mentioned undertakings:

- The Company hereby undertakes that it shall, if required to do so, re-compute the price of the specified securities in terms of the provision of SEBI ICDR Regulations;

- Further, it undertakes that, if the amount payable on account of the re-computation of price is not paid within the time stipulated in SEBI ICDR Regulations, the Equity Shares and Warrants shall continue to be locked-in till the time such amount is paid by the allottees.

All other particulars and details of the EGM Notice remain unchanged. The corrigendum shall be read in conjunction with the Notice dated July 10, 2026 together with explanatory statement. This corrigendum is also available on the company's website at https://www.indswiftgroup.com/investor/preferential-issue/, and on the website of National Stock Exchange of India Limited **("NSE")** at https://www.nseindia.com/ and BSE Limited **("BSE")** at https://www.bseindia.com/ respectively. The corrigendum shall also be sent electronically to all the registered shareholders of the Company.

For **Ind-Swift Laboratories Limited**

Sd/-
Pardeep Verma
VP - Corporate Affairs & Company Secretary
M. No. F4387

Date: July 29, 2026
Place: Chandigarh